Clinton, CT, United States of America

Yasutsugu Ueda

USPTO Granted Patents = 31 

 

Average Co-Inventor Count = 7.9

ph-index = 11

Forward Citations = 388(Granted Patents)


Location History:

  • Clinton, CT (US) (1993 - 2014)
  • Wallingford, CT (US) (2022)

Company Filing History:


Years Active: 1993-2022

Loading Chart...
Loading Chart...
31 patents (USPTO):

Title: **Yasutsugu Ueda: Innovator in Antiviral Agents**

Introduction

Yasutsugu Ueda is a notable inventor based in Clinton, CT, recognized for his extensive contributions to pharmaceutical innovations, with a remarkable portfolio of 31 patents. His work focuses on developing antiviral agents, specifically aimed at combating diseases such as HIV.

Latest Patents

Among his latest inventions is the patent titled "Salts of prodrugs of piperazine and substituted piperidine antiviral agents." This invention introduces prodrug Compounds I, which can be formulated into pharmaceutical compositions for the effective treatment of HIV infection. Additionally, the invention details intermediate Compounds II that are essential in synthesizing the prodrug Compounds I, highlighting Ueda's innovative approach in enhancing antiviral therapies.

Career Highlights

Throughout his career, Ueda has made significant strides in the pharmaceutical industry, particularly while working with Bristol-Myers Squibb Company. His role in this leading biopharmaceutical firm allowed him to refine his expertise and focus on the development of innovative treatment solutions for various diseases.

Collaborations

Ueda has collaborated with esteemed colleagues including John D. Matiskella and Timothy P. Connolly. These partnerships have fostered innovative research and product development, underlining the importance of teamwork in achieving groundbreaking advancements in medicine.

Conclusion

In summary, Yasutsugu Ueda stands out as a prominent inventor whose contributions to antiviral research are noteworthy. With a robust portfolio of patents and valuable collaborations, he continues to push the boundaries of innovation in the pharmaceutical field, aiming to improve therapies for infectious diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…